Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer
Launched by UNIVERSITY OF WISCONSIN, MADISON · Jul 25, 2022
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how certain imaging tests and gene expressions can help predict how well patients with high-risk prostate cancer will respond to their treatment. The treatments being looked at include external beam radiation therapy, a type of internal radiation called brachytherapy, and hormone therapy. If you are an adult man aged 18 or older with high-risk prostate cancer, you may qualify to participate. To be eligible, you need to have a specific type of prostate cancer and agree to undergo the mentioned treatments.
Participants in this study can expect to be involved for up to five years. Throughout this time, researchers will closely monitor your health and treatment responses using advanced imaging and genetic tests. This information could help doctors improve treatment options for future patients with prostate cancer. It's important to know that the trial is currently recruiting participants, so if you or someone you know is interested, it could be a great opportunity to contribute to cancer research while receiving standard care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18
- • Histologically confirmed adenocarcinoma of the prostate
- • Cancer classified as high-risk or very high-risk by National Comprehensive Cancer Network (NCCN) criteria: Grade group ≥4, PSA \>20, or primary tumor stage ≥T3a
- • ECOG performance status 0-1
- • Agreed to undergo EBRT, high dose rate (HDR) brachytherapy boost, and 6-36 months of ADT as part of standard of care therapy prior to study enrollment
- • Able to undergo a HDR brachytherapy implant: Pre-radiation IPSS score ≤20 with or without medical management; prostate ≤60 cc as measured by MRI or ultrasound; no prior trans-urethral resection of prostate (TURP); and, median lobe extending into the bladder \<1 cm
- • No prior or concurrent malignancy unless disease-free for at least 5 years
- Exclusion Criteria:
- • Evidence of regional or distant metastatic disease on pre-treatment bone scan, pelvic MRI, and/or CT of the abdomen/pelvis
- • Prior pelvic radiation therapy
About University Of Wisconsin, Madison
The University of Wisconsin-Madison is a leading research institution renowned for its commitment to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its extensive resources, including cutting-edge facilities and a diverse pool of expert researchers, to conduct rigorous studies that address critical health challenges. The institution's focus on translating research findings into practical applications fosters the development of new treatments and interventions, ultimately contributing to improved patient outcomes and public health initiatives. As a sponsor of clinical trials, the University of Wisconsin-Madison is dedicated to upholding the highest ethical standards and ensuring participant safety throughout the research process.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madison, Wisconsin, United States
Madison, Wisconsin, United States
Patients applied
Trial Officials
John Floberg, MD, PhD
Principal Investigator
University of Wisconsin, Madison
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials